How using carotid artery ultrasounds affects taking cholesterol medications
Not Applicable
- Conditions
- ow statin adherence in apparently healthy individuals with high and very high CVD risk.Circulatory System
- Registration Number
- ISRCTN10591599
- Lead Sponsor
- KRKA, tovarna zdravil, d.d., Novo Mesto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 380
Inclusion Criteria
1. Aged 40 to 69 years
2. CVD risk evaluated as high or very high
3. No prior use of antilipemic drugs
Exclusion Criteria
1.Diabetes mellitus type 1 or type 2
2.Carotid ultrasound conducted in the past 5 years
3.Chronic kidney disease
4.Previously known cvd
5.Family hypercholesterolemia
6.Active malignant disease
7.Difficult to manage” psychiatric disorder
8.Language barrier (subject’s knowledge of slovene language is inadequate for appropriate communication with physician)
9.Estimated life expectancy of less than 1 year.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting blood LDL cholesterol levels will be measured using blood test before intervention and 9 months after intervention.
- Secondary Outcome Measures
Name Time Method 1. Prevalence of atherosclerotic plaques in the carotid arteries of apparently healthy individuals with risk factors measured using ultrasonographic recording at baseline for intervention group, at 9 months for controlled group<br>2. Sensitivity and specificity of identifying atherosclerotic plaques using carotid artery POCUS performed by family medicine physicians measured using ultrasonographic recording at baseline for intervention group, at 9 months for controlled group<br>3. Assess how the presence of atherosclerotic plaques visible to the patient affects adherence to lipid-lowering medications measured using difference in LDL cholesterol levels at baseline and in 9 months time<br>4. Determine how the presence of atherosclerotic plaques identified by the physician influences the intensity of the prescribed therapy measured by observing doses of prescribed medications at 6 months